PhRMA’s Medicare Demos Would Pair Voluntary Price Discounts With Reduced Cost Sharing
Whether an opening gambit for negotiation or the most industry is willing to concede, proposals being offered by industry to replace the Trump Administration’s plan to pursue international reference pricing for Part B drugs seem modest.
You may also be interested in...
Obamacare repeal has been replaced by rebrand as Trump administration plans to use ACA’s Medicare demonstration powers to send discount cards to seniors, one of a slew of health care announcements that include Rx importation, pre-existing conditions, insulin and EpiPens.
Under test payment model, Medicare would pay no more than most-favored-nation price for Part B and Part D drugs, but how and when the model program would be implemented remains unclear. BIO may pursue legal action as questions on how plan would be implemented and if the administration will provide notice and comment period for stakeholder input remain.
Merck & Co’s chief executive shares views on the need for “reasonable” returns on COVID-19 therapeutics and vaccines, and on the future US pricing environment, at the USAIC summit.